tau inhibitor / APRINOIA Therap - LARVOL DELTA

APNmAb005, an anti-tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies (AAIC 2023) - "APNmAb005 is a conformation selective antibody that binds to tau oligomers and aggregates preferentiually in synapses in pathological brain tissues and inhibits tau spreading. The mid-region conformation dependent epitope is distinct from all other tau antibodies currently in clinical development. APNmAb005 offers a unique tau immunotherapy for neurodegenerative disorders and is currently in Phase 1 to evaluate its safety and tolerability."

P1 data • Alzheimer's Disease • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • Solid Tumor